Fortress Biotech, Inc. (94) | Business Finance (15)
Browse by Subcategory
Recent Contracts
-
Form of Securities Purchase Agreement, dated February 7, 2023, by and among the Company and the purchasers party thereto
(Filed With SEC on February 9, 2023)
-
Form of Contingent Subsidiary Security
(Filed With SEC on February 9, 2023)
-
Form of Restricted Stock Unit Agreement (David Jin)
(Filed With SEC on October 28, 2022)
-
Credit Agreement entered into by and among Fortress Biotech, Inc., the lenders from time to time party thereto, and Oaktree Fund Administration, LLC on August 27, 2020
(Filed With SEC on August 16, 2021)
-
Asset Purchase Agreement entered into by and between Sentynl Therapeutics, Inc. and Cyprium Therapeutics, Inc. dated as of February 23, 2021
(Filed With SEC on August 16, 2021)
-
Asset Purchase Agreement entered into by and between Journey Medical Corporation and Dermira, Inc. dated as of March 31, 2021
(Filed With SEC on August 16, 2021)
-
Credit Agreement entered into by and among Fortress Biotech, Inc., the lenders from time to time party thereto, and Oaktree Fund Administration, LLC on August 27, 2020
(Filed With SEC on May 17, 2021)
-
Asset Purchase Agreement entered into by and between Sentynl Therapeutics, Inc. and Cyprium Therapeutics, Inc. dated as of February 23, 2021
(Filed With SEC on May 17, 2021)
-
Asset Purchase Agreement entered into by and between Journey Medical Corporation and Dermira, Inc. dated as of March 31, 2021
(Filed With SEC on May 17, 2021)
-
Credit Agreement entered into by and among Fortress Biotech, Inc., the lenders from time to time party thereto, and Oaktree Fund Administration, LLC on August 27, 2020
(Filed With SEC on November 9, 2020)
-
Underwriting Agreement, dated August 26, 2020, by and among Fortress Biotech, Inc., The Benchmark Company, LLC and ThinkEquity, a division of Fordham Financial Management, Inc
(Filed With SEC on August 28, 2020)
-
Underwriting Agreement, dated May 26, 2020, by and among Fortress Biotech, Inc., The Benchmark Company, LLC and ThinkEquity, a division of Fordham Financial Management, Inc
(Filed With SEC on May 28, 2020)
-
Underwriting Agreement, dated February 11, 2020, between Fortress Biotech, Inc., The Benchmark Company, LLC and ThinkEquity, a division of Fordham Financial Management, as...
(Filed With SEC on February 12, 2020)
-
Underwriting Agreement, dated November 25, 2019, between Fortress Biotech, Inc., The Benchmark Company, LLC and ThinkEquity, a division of Fordham Financial Management, as...
(Filed With SEC on November 26, 2019)
-
Development, Option and Stock Purchase Agreement dated January 30, 2019 by and among Fortress Biotech, Inc., Caelum Biosciences, Inc. (Caelum), Alexion Therapeutics, Inc., and the...
(Filed With SEC on May 10, 2019)